我要投票 华峰制药在医疗器械行业中的票数:261
· 外 推 电 报 ·
2025-06-25 19:36:20 星期三

【华峰制药是哪个国家的品牌?】

华峰制药是什么牌子?「华峰制药」是 河南华峰制药有限公司 旗下著名品牌。该品牌发源于河南省濮阳市,由创始人娄 *在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力华峰制药品牌出海!将品牌入驻外推网,定制华峰制药品牌推广信息,可以显著提高华峰制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

河南华峰制药有限公司是2000年5月经国家有关部委批准成立的股份制企业,现有资产5000万元, 厂区占地面积3万平方米,建筑面积2万平方米,占地62亩的二期工程正在筹建中。公司拥有各类高、中级技术人员200余人,专业营销人员100余人。公司地处园林城、卫生城、文明城、旅游城濮阳市高新技术产业开发区。西有濮阳的绿色庄园、濮上园等城市标志性旅游景点,东临南北走向的城市绿化森林,环境幽雅,交通便利 。

河南华峰制药有限公司以开发治疗骨病系列药品为主,承担着国家治疗骨病骨伤研发药品的项目,目前拥有生产国药准字号丸剂、酒剂及膏药等六个剂型共20多个品种, 形成了具有传统中医药生产销售与临床推广为一体的经营新格局,公司以开发骨病治疗药品为主,承担着国家治疗骨病研究的项目,公司自行研制生产的“娄峰”牌正骨膏、治伤消瘀丸、风湿骨病丸、祛风湿膏、骨痛药酒等,以其品质及适应性赢得了广大用户的认可,在医院专科专病建设领域树立了品牌。公司产品市场销售及医疗服务网络涉及东北地区、北京、山东、山西、安徽、江苏、上海等省市700多家医疗单位,创出了一条医疗服务和药品销售相结合的经营新模式,形成了区域拓展广阔的销售网络。

华峰公司将发展领域定位于人类健康产业,即中医药产业。专注于骨科病等病症的名优中成药,实施名牌战略,中药现代化和产业化的接轨,高度重视以市场为导向,具有前沿技术的研发能力的培育,完善以顾客为导向的营销战略,保障在行业中保持优势的竞争地位。华峰核心竞争力源于企业核心技术能力、应变能力、组织协调能力和企业影响力。华峰注重企业文化的建设借以形成能力出众、卓识创新的人才群体,打造高水准的华峰营销模式,不断改进华峰的管理和生产模式,提高华峰品质,以形成华峰的市场竞争力。

进入新世纪,经济全球化、全球信息化、知识经济新时代已经来临,它对公司现有的生产方式、生活方式、思维方式、管理方式等都将产生重大影响,必将引发企业管理上的新一轮创新性的革命。华峰全体员工将认清形势,持续不断地开展观念创新、知识创新、管理创新、市场创新、机制创新、技术创新、质量创新、产品创新,以求真、务实、创新的精神和干劲,保持企业稳健、持续发展,做行业先锋,创世纪品牌。

成熟的技术,优良的设备,科学的管理,使河南华峰制药有限公司成为研发与生产治疗骨病系列药品的优势企业,在全国地区的中药制药现代化进程中焕发出无限生机。


英文翻译:Henan Huafeng Pharmaceutical Co., Ltd. is a joint-stock enterprise established in May 2000 with the approval of the relevant ministries and commissions of the state. The current assets are 50 million yuan, the plant covers an area of 30000 square meters, the building area is 20000 square meters, and the second phase project covering 62 Mu is under preparation. The company has more than 200 high and intermediate technical personnel and more than 100 professional marketing personnel. The company is located in the park city, health city, civilization city, tourism city Puyang high tech Industrial Development Zone. In the west, there are the Green Manor of Puyang, the park of pushangyuan and other urban landmark tourist attractions. In the East, there is the North-South urban green forest, with elegant environment and convenient transportation. Henan Huafeng Pharmaceutical Co., Ltd. is mainly engaged in the development of a series of drugs for the treatment of osteopathy, and undertakes the national research and development of drugs for the treatment of osteopathy and osteopathy. At present, it has produced more than 20 varieties of six dosage forms, such as Guoyao Zhun brand pills, liquors and plasters, forming a new business pattern with the integration of traditional Chinese medicine production and sales and clinical promotion. The company focuses on the development of drugs for the treatment of osteopathy The company has undertaken the national research project of bone disease treatment. The company has developed and produced "Loufeng" brand bone paste, zhishangxiaoyu pill, Fengshi bone disease pill, Qufengshi ointment, bone pain medicine liquor, etc., which have won the recognition of the majority of users for their quality and adaptability, and established a brand in the field of hospital specialized disease construction. The company's product market sales and medical service network involve more than 700 medical units in Northeast China, Beijing, Shandong, Shanxi, Anhui, Jiangsu, Shanghai and other provinces and cities. It has created a new business model combining medical service and drug sales, and formed a wide regional sales network. Huafeng company will focus on the development of human health industry, that is, traditional Chinese medicine industry. Focus on famous and excellent Chinese patent medicines for orthopedic diseases, implement the famous brand strategy, integrate the modernization and industrialization of traditional Chinese medicine, attach great importance to the cultivation of market-oriented, cutting-edge technology research and development ability, improve customer-oriented marketing strategy, and ensure the competitive position in the industry. The core competitiveness of Huafeng comes from the core technology ability, adaptability, organization and coordination ability and enterprise influence. Huafeng attaches great importance to the construction of corporate culture so as to form a talent group with outstanding ability and outstanding innovation, build a high-level marketing mode, constantly improve the management and production mode of Huafeng, improve the quality of Huafeng, and form the market competitiveness of Huafeng. In the new century, the new era of economic globalization, global information and knowledge economy has come. It will have a significant impact on the company's existing production mode, life style, thinking mode, management mode, etc., and will inevitably lead to a new round of innovative revolution in enterprise management. All staff of Huafeng will recognize the situation, continuously carry out concept innovation, knowledge innovation, management innovation, market innovation, mechanism innovation, technology innovation, quality innovation and product innovation, keep the enterprise steady and sustainable development, be the industry leader and create century brand with the spirit and drive of truth-seeking, pragmatic and innovation. With mature technology, excellent equipment and scientific management, Henan Huafeng Pharmaceutical Co., Ltd. has become an advantageous enterprise in R & D and production of series drugs for treating bone disease, which is full of infinite vitality in the process of modernization of traditional Chinese medicine in the whole country.

本文链接: https://www.waitui.com/brand/e4731c9c9.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

指南针:公司不存在违反公平信息披露规定的情形

36氪获悉,指南针公告,经核实,公司前期披露的信息不存在需要更正、补充之处;公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息;公司目前的经营情况及内外部经营环境未发生重大变化;公司、控股股东及实际控制人不存在关于公司应披露而未披露的重大事项,或处于筹划阶段的重大事项;股票异常波动期间,不存在控股股东、实际控制人买卖公司股票的行为;公司不存在违反公平信息披露规定的情形。

2小时前

小鹏汽车:海外市场正在收紧零公里二手车的进口,小鹏并未采用这一出口模式

小鹏汽车国际业务中心总经理唐志坤表示,国内有大量汽车通过“零公里二手车”模式出口,目的地包括中东、北非、中亚等,体量“诱人”,确实可以贡献很大销量。但小鹏对此是克制的,并没有采用这一出口模式来增加短期销量。他透露,从今年来看,其实很多海外市场的政府正在收紧这个开口,通过法规、认证等方式陆续禁止零公里二手车进口。(澎湃)

2小时前

国泰君安国际获南向资金净买入16.62亿港元

南向资金大幅净买入95.74亿港元,国泰君安国际、中芯国际、建设银行分别获净买入16.62亿港元、14.25亿港元、8.93亿港元;腾讯控股净卖出额居首,金额为5.52亿港元。(第一财经)

2小时前

神州细胞:控股子公司产品SCTB39G获得药物临床试验批准通知书

36氪获悉,神州细胞公告,公司控股子公司神州细胞工程有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意公司自主研发的产品SCTB39G注射液单药在晚期实体瘤患者中开展临床试验。该产品为公司自主研发的多靶点免疫治疗三特异性抗体注射液。

2小时前

《新世界加载中》在北京举行首映礼

36氪获悉,6月25日,由快手可灵AI与星芒短剧联合出品、异类Outliers团队制作的全球首部AI单元故事集《新世界加载中》在北京举行首映礼。据了解,《新世界加载中》借助快手自研视频生成大模型可灵AI创作而成,通过突破性的AIGC技术和深刻的故事主题,定义了AI技术在短剧创作中的全新可能。自去年6月发布以来,可灵AI已累计完成超20次迭代,截至目前,全球用户规模突破2200万。

2小时前

本页详细列出关于华峰制药的品牌信息,含品牌所属公司介绍,华峰制药所处行业的品牌地位及优势。
咨询